Table 2.
Patient characteristics between the “continent” and the “incontinent” group.
| Total (n = 84) | Continent (n = 50) | Incontinent (n = 34) | p-value | ||
|---|---|---|---|---|---|
| Age (years) | Median (min; max) | 64 (48;78) | 64 (48;78) | 65 (58;78) | 0.22 |
| BMI (kg/m²) | BMI <24 | 9 (10.7 %) | 6 (66.7 %) | 3 (33.3 %) | 0.78 |
| BMI 24–<30 | 58 (69.0 %) | 35 (60.3 %) | 23 (39.7 %) | ||
| BMI 30–<35 | 14 (16.7 %) | 8 (57.1 %) | 6 (42.9 %) | ||
| BMI ≥35 | 3 (3.6 %) | 1 (33.3 %) | 2 (66.7 %) | ||
| iPSA (ng/ml) | <4 | 4 (4.8 %) | 3 (75.0 %) | 1 (25.0 %) | 0.12 |
| 4–<10 | 51 (60.7 %) | 30 (58.8 %) | 21 (41.2 %) | ||
| 10–<20 | 17 (20.2 %) | 13 (76.5 %) | 4 (23.5 %) | ||
| ≥20 | 12 (14.3 %) | 4 (33.3 %) | 8 (66.7 %) | ||
| Prostate volume (ml) | <40 | 39 (46.4 %) | 18 (46.2 %) | 21 (53.8 %) | 0.05 |
| 40–90 | 43 (51.2 %) | 30 (69.8 %) | 13 (30.2 %) | ||
| >90 | 2 (2.4 %) | 2 (100 %) | 0 | ||
| IPSS (preoperative) | <8 | 47 (57.3 %) | 32 (68.1 %) | 15 (31.9 %) | 0.16 |
| 8–19 | 31 (37.8 %) | 17 (54.8 %) | 14 (45.2 %) | ||
| 20–35 | 4 (4.9 %) | 1 (25.0 %) | 3 (75.0 %) | ||
| ICIQ (preoperative) | No incon. | 58 (75.3 %) | 35 (60.3 %) | 23 (39.7 %) | 0.45 |
| Light incon. | 14 (18.2 %) | 8 (57.1 %) | 6 (42.9 %) | ||
| Mid incon. | 1 (1.3 %) | 1 (100 %) | 0 | ||
| Severe incon. | 4 (5.2 %) | 1 (25.0 %) | 3 (75.0 %) | ||
| pT status | pT2 | 14 (16.7 %) | 9 (64.3 %) | 5 (35.7 %) | 0.92 |
| pT3-4 | 70 (83.3 %) | 41 (58.6 %) | 29 (41.4 %) | ||
| pN status | pN0 | 78 (94.0 %) | 48 (61.5 %) | 30 (38.5 %) | 0.17 |
| pN1 | 5 (6.0 %) | 1 (20.0 %) | 4 (80.0 %) | ||
| R status | R0 | 61 (72.6 %) | 39 (63.9 %) | 22 (36.1 %) | 0.25 |
| R1 | 22 (26.2 %) | 11 (50.0 %) | 11 (50.0 %) | ||
| R2 | 1 (1.2 %) | 0 | 1 (100 %) | ||
| GS | 6 | 1 (1.2 %) | 0 | 1 (100 %) | 0.03 |
| 7 | 65 (77.4 %) | 43 (66.2 %) | 22 (33.8 %) | ||
| 8 | 4 (4.8 %) | 0 | 4 (100 %) | ||
| 9 | 14 (16.7 %) | 7 (50.0 %) | 7 (50.0 %) | ||
| NS | Unilateral NS | 27 (32.1 %) | 11 (40.7 %) | 16 (59.3 %) | 0.01 |
| Bilateral NS | 25 (29.8 %) | 21 (84.0 %) | 4 (16.0 %) | ||
| No NS | 32 (38.1 %) | 18 (56.2 %) | 14 (43.8 %) | ||
| Pelvic floor training preoperative | Yes | 13 (23.6 %) | 9 (69.2 %) | 4 (30.8 %) | 0.30 |
| No | 42 (76.4 %) | 20 (47.6 %) | 22 (52.4 %) | ||
| MMSE | Good | 53 (65.4 %) | 31 (58.5 %) | 22 (41.5 %) | 0.44 |
| Intermediate | 26 (32.1 %) | 14 (53.8 %) | 12 (46.2 %) | ||
| Bad | 2 (2.5 %) | 2 (100 %) | 0 | ||
| Catheterization time (after RALP) | ≤7 days | 78 (92.9 %) | 47 (60.3 %) | 31 (39.7 %) | 0.95 |
| ≥8 days | 6 (7.1 %) | 3 (50.0 %) | 3 (50.0 %) |
(min, minimum; max, maximum; BMI, Body Mass Index; iPSA, initial prostate specific antigen; ng/ml, nanogram per milliliter; ml, milliliter; IPSS, international prostate symptom score; ICIQ, international consultation of continence questionnaire; incon., incontinence; GS, Gleason Score; NS, nerve sparing; MMSE, Mini-Mental State Examination; RALP, robot-assisted laparoscopic prostatectomy).